Form 4: Unity Biotechnology Director Acquires Stock Options

Gilmore Neil O'Neill, a director at Unity Biotechnology, acquired stock options for 10,000 shares of common stock on June 21, 2024.

Summary

• On June 21, 2024, Gilmore Neil O'Neill, a director of Unity Biotechnology, acquired stock options to purchase 10,000 shares of the company's common stock.
• The exercise price of the options is $1.38 per share.
• The options vest 100% on the earlier of June 21, 2025, or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director.
• The options expire on June 20, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring stock options suggests confidence, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent on continued service as a director, suggesting an expectation of ongoing involvement with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates